Alexander Levitzki

Alexander Levitzki's AcademicInfluence.com Rankings

Alexander Levitzki

Biology

#1590

World Rank

#2621

Historical Rank

Biochemistry

#211

World Rank

#266

Historical Rank

Neuroscience

#486

World Rank

#505

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Alexander Levitzki Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Alexander Levitzki is an Israeli biochemist who is a professor of biochemistry at the Alexander Silberman Institute of Life Sciences, the Hebrew University of Jerusalem. Birth and education Levitzki was born in 1940 in Palestine. He completed his M.Sc. in chemistry from the Hebrew University of Jerusalem in Israel. He received his Ph.D. in biochemistry and biophysics from the Hebrew University of Jerusalem and the Weizmann Institute of Science, in 1968. From 1968 to 1971, he was a post-doctoral fellow at the Department of Biochemistry, University of California at Berkeley in California, with Professor Daniel E. Koshland, Jr., where he worked in particular on negative cooperativity and half-of-the-sites reactivity. Contrary to the common misconception, Levitzki is not a descendant of the Hebrew Levite tribe.

(See a Problem?)

Alexander Levitzki's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. (1999) (1730)
Tyrosine kinase inhibition: an approach to drug development. (1995) (1231)
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor (1996) (955)
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells (2001) (775)
EGF induces tyrosine phosphorylation of phospholipase C-II: A potential mechanism for EGF receptor signaling (1989) (609)
ROS, stress‐activated kinases and stress signaling in cancer (2002) (603)
Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors (1988) (589)
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. (1989) (569)
Transglutaminase is essential in receptor-mediated endocytosis of α2-macroglobulin and polypeptide hormones (1980) (497)
Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. (1999) (407)
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. (1998) (374)
Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. (1994) (358)
Flk-1 as a target for tumor growth inhibition. (1996) (335)
Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress (2001) (323)
The effect of tyrosine‐specific protein phosphorylation on the assembly of adherens‐type junctions. (1992) (319)
Mode of coupling between the beta-adrenergic receptor and adenylate cyclase in turkey erythrocytes. (1978) (314)
Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction (1992) (297)
Epidermal-growth-factor-dependent activation of the src-family kinases. (1994) (287)
Negative cooperativity in regulatory enzymes. (1969) (280)
Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. (1994) (279)
Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. (1989) (267)
Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors (1999) (253)
From epinephrine to cyclic AMP. (1988) (244)
Metal-binding sites of concanavalin A and their role in the binding of alpha-methyl d-glucopyranoside. (1968) (238)
Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. (1991) (238)
Protein tyrosine kinase inhibitors as novel therapeutic agents. (1999) (217)
Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. (1996) (207)
Tyrphostins and other tyrosine kinase inhibitors. (2006) (206)
Mode of coupling between hormone receptors and adenylate cyclase elucidated by modulation of membrane fluidity (1978) (195)
Half-of-the-sites reactivity and the conformational states of cytidine triphosphate synthetase. (1971) (190)
Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. (1993) (188)
PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. (1998) (183)
Tyrphostins--potential antiproliferative agents and novel molecular tools. (1990) (182)
Adenylate cyclase activation by the beta-adrenergic receptors as a diffusion-controlled process. (1979) (181)
Activation of Stat3 in v-Src-transformed Fibroblasts Requires Cooperation of Jak1 Kinase Activity* (2000) (175)
Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. (2013) (173)
Substrate competitive inhibitors of IGF-1 receptor kinase. (2000) (159)
Signal-transduction therapy. A novel approach to disease management. (1994) (156)
Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor (2006) (156)
Cisplatin-induced activation of the EGF receptor (2002) (150)
Protein kinase inhibitors as a therapeutic modality. (2003) (148)
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. (2002) (146)
Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. (1997) (143)
Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. (1997) (135)
Tyrphostins as molecular tools and potential antiproliferative drugs. (1991) (128)
Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 Receptor-insulin receptor substrate and STAT3 signaling (2015) (124)
Activated pp60c-Src Leads to Elevated Hypoxia-inducible Factor (HIF)-1α Expression under Normoxia* (2002) (124)
Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics* (2003) (121)
Beta-adrenergic receptors and their mode of coupling to adenylate cyclase. (1986) (120)
The binding characteristics and number of beta-adrenergic receptors on the turkey erythrocyte. (1974) (117)
The Allosteric Activation of Mammalian α‐Amylase by Chloride (1974) (117)
The role of negative cooperativity and half-of-the-sites reactivity in enzyme regulation. (1976) (116)
Signal-transduction therapy (1994) (115)
Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. (1993) (113)
EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice (2005) (112)
The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. (1991) (112)
A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. (1999) (112)
The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. (1993) (111)
The control of adenylate cyclase by calcium in turkey erythrocyte ghosts. (1975) (111)
Therapeutic destruction of insulin receptor substrates for cancer treatment. (2013) (108)
Evidence for participation of transglutaminase in receptor-mediated endocytosis. (1980) (107)
Activation of the Ras/Mitogen-Activated Protein Kinase Pathway by Kinase-Defective Epidermal Growth Factor Receptors Results in Cell Survival but Not Proliferation (1998) (105)
Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. (2002) (104)
Targeting signal transduction for disease therapy. (1996) (104)
Role of an allosteric effector. Guanosine triphosphate activation in cytosine triphosphate synthetase. (1972) (101)
Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. (1996) (98)
Signal transduction by a nondissociable heterotrimeric yeast G protein. (2000) (98)
Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins. (1997) (97)
Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. (1991) (97)
Killing time for cancer cells (2005) (95)
Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. (1992) (94)
Cytidine triphosphate synthetase. Covalent intermediates and mechanisms of action. (1971) (94)
Coupling of a single adenylate cyclase to two receptors: adenosine and catecholamine. (1978) (93)
Dimerization of Ste5, a mitogen-activated protein kinase cascade scaffold protein, is required for signal transduction. (1996) (93)
Reconstitution of membrane receptor systems. (1985) (92)
Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier (2011) (90)
Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. (1994) (87)
Ligand-induced dimer-to-tetramer transformation in cytosine triphosphate synthetase. (1972) (85)
Signal transduction therapy of cancer. (2010) (85)
Isolation of Hyperactive Mutants of the MAPK p38/Hog1 That Are Independent of MAPK Kinase Activation* (2001) (84)
PDGF receptor kinase inhibitors for the treatment of restenosis. (2005) (83)
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. (2001) (83)
Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by Lavendustin-A and its analogue. (1991) (81)
Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase (2001) (81)
PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. (2004) (80)
Molecular basis of negative co-operativity in rabbit muscle glyceraldehyde-3-phosphate dehydrogenase. (1974) (79)
Information-theoretic analysis of phenotype changes in early stages of carcinogenesis (2010) (79)
Reconstitution of beta 1‐adrenoceptor‐dependent adenylate cyclase from purified components. (1986) (78)
Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. (2006) (78)
Half-of-the-sites and all-of-the-sites reactivity in rabbit muscle glyceraldehyde 3-phosphate dehydrogenase. (1974) (78)
The pp60c‐Src inhibitor PP1 is non‐competitive against ATP (2003) (77)
Inhibition of protein-tyrosine kinases by tyrphostins. (1991) (76)
Phosphorylation of the S. cerevisiae Cdc25 in response to glucose results in its dissociation from Ras (1992) (76)
Stereospecific binding of propranolol and catecholamines to the beta-adrenergic receptor. (1974) (75)
The subunit structure and subunit interactions of cytidine triphosphate synthetase. (1970) (75)
The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers (1991) (74)
Regulation of adenylate cyclase by hormones and G‐proteins (1987) (73)
Binding of lanthanides and of divalent metal ions to porcine trypsin. (1974) (73)
Targeting the EGFR and the PKB pathway in cancer. (2009) (73)
Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. (1994) (73)
High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. (2005) (72)
Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. (2007) (70)
Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. (1996) (70)
The copper-poly-L-histidine complex. I. The environmental effect of the polyelectrolyte on the oxidase activity of copper ions. (1967) (69)
Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. (2000) (69)
Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. (2004) (69)
Kinetics of interaction between beta-receptors, GTP protein, and the catalytic unit of turkey erythrocyte adenylate cyclase. (1982) (68)
Inhibition of glioma growth by tumor-specific activation of double-stranded RNA–dependent protein kinase PKR (2002) (67)
Labeled EGFr‐TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug (2002) (67)
Ligand specificity and characteristics of the beta-adrenergic receptor in turkey erythrocyte plasma membranes. (1975) (66)
Tyrosine kinases as targets for cancer therapy. (2002) (65)
Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. (2005) (65)
Active Src Elevates the Expression of β-Catenin by Enhancement of Cap-Dependent Translation (2005) (64)
Negative co-operativity in clustered receptors as a possible basis for membrane action. (1974) (64)
Synergistic activation of adenylate cyclase by guanylyl imidophosphate and epinephrine. (1976) (63)
An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves. (1987) (63)
Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. (1995) (63)
EGF receptor as a therapeutic target. (2003) (62)
Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation. (1991) (62)
Cellular Receptors for Hormones and Neurotransmitters (1980) (61)
G‐Protein Subunit Dissociation Is not an Integral Part of G‐Protein Action (2002) (59)
PolyIC GE11 polyplex inhibits EGFR‐overexpressing tumors (2012) (59)
Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. (1997) (59)
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. (2003) (58)
Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents (2010) (58)
Reconstitution of beta‐adrenergic receptor with components of adenylate cyclase. (1984) (57)
Adenosine receptor permanently coupled to turkey erythrocyte adenylate cyclase. (1979) (57)
Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. (1997) (56)
Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. (2002) (56)
Transmembrane signaling in Saccharomyces cerevisiae as a model for signaling in metazoans: state of the art after 25 years. (2014) (55)
Platelet-derived Growth Factor Requires Epidermal Growth Factor Receptor to Activate p21-activated Kinase Family Kinases* (2001) (55)
Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. (2004) (54)
Regulation of hormone-sensitive adenylate cyclase (1987) (54)
Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. (1998) (54)
Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. (2001) (54)
On a fundamental structure of gene networks in living cells (2012) (53)
Inhibition of platelet activation by tyrosine kinase inhibitors. (1992) (52)
Kinetic model of the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF. (1992) (52)
Microwave-assisted solid-phase aza-peptide synthesis: aza scan of a PKB/Akt inhibitor using aza-arginine and aza-proline precursors. (2011) (50)
Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. (1996) (50)
Receptors: A Quantitative Approach (1984) (50)
Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. (1997) (50)
The activation of adenylate cyclase by guanyl nucleotides in Saccharomyces cerevisiae is controlled by the CDC25 start gene product (1987) (49)
Inhibition of insulin‐dependent lipogenesis and anti‐lipolysis by protein tyrosine kinase inhibitors. (1989) (48)
The regulation of adenylyl cyclase by receptor-operated G proteins. (1991) (47)
Determination of submicro quantities of ammonia. (1970) (47)
Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. (1998) (47)
The role of GTP in the activation of adenylate cyclase. (1977) (46)
Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors (1999) (45)
Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity. (1996) (43)
Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). (2007) (43)
Transmembrane signalling in Saccharomyces cerevisiae. (1989) (42)
Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro. (1996) (42)
Stimulatory GTP regulatory unit Ns and the catalytic unit of adenylate cyclase are tightly associated: mechanistic consequences. (1984) (41)
The copper-poly-L-histidine complexes. II. Physicochemical properties. (1972) (41)
Calcium binding site of trypsin as probed by lanthanides. (1977) (41)
Anomalous Features of EMT during Keratinocyte Transformation (2008) (41)
Targeting signal transduction for disease therapy (1997) (40)
Up-regulation of AMP-activated Protein Kinase in Cancer Cell Lines Is Mediated through c-Src Activation* (2011) (40)
Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. (1999) (40)
Inter-Relations between β-Adrenergic Receptors, Adenylate Cyclase and Calcium (1975) (40)
Tentative identification of β-adrenoreceptor subunits (1978) (39)
The Tyr-Kinase Inhibitor AG879, that Blocks the ETK-PAK1 Interaction, Suppresses the RAS-induced PAK1 Activation and Malignant Transformation (2004) (39)
Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. (1992) (38)
A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. (2007) (38)
Ligand induced half-of-the-sites reactivity in rabbit muscle glyceraldehyde-3-phosphate dehydrogenase. (1973) (38)
In vitro reconstitution of cdc25 regulated S. cerevisiae adenylyl cyclase and its kinetic properties. (1990) (38)
Residues crucial for Ras interaction with GDP-GTP exchangers. (1993) (38)
Probing of β-adrenergic receptors by novel fluorescent β-adrenergic blockers (1977) (37)
Specific precipitation of enzyme by its substrate: the α-amylase-macrodextrin complex (1964) (37)
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. (2011) (36)
The absence of desensitization in the beta adrenergic receptors of turkey reticulocytes and erythrocytes and its possible origin. (1978) (36)
Receptor to effector coupling in the receptor-dependent adenylate cyclase system. (1984) (36)
Identity and properties of the chloride effector binding site in hog pancreatic alpha-amylase. (1976) (35)
Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. (2001) (35)
Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. (1993) (34)
SRC as a target for anti-cancer drugs. (1996) (34)
Activation and inhibition of adenylate cyclase by hormones: mechanistic aspects (1982) (34)
Novel method for the synthesis of urea backbone cyclic peptides using new Alloc‐protected glycine building units (2010) (33)
Targeted cancer immunotherapy. (2013) (33)
The allosteric inhibition by calcium of soluble and partially purified adenylate cyclase from turkey erythrocytes. (1977) (33)
Tyrphostins suppress the growth of psoriatic keratinocytes (1995) (33)
The metal specificity of mammalian α‐amylase as revealed by enzyme activity and structural probes (1973) (33)
Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. (1993) (33)
Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling (2016) (33)
Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. (2004) (33)
Temperature dependence of beta receptor, adenosine receptor, and sodium fluoride stimulated adenylate cyclase from turkey erythrocytes. (1980) (32)
Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway (2000) (32)
Cooperativity in associating proteins. Monomer-dimer equilibrium coupled to ligand binding. (1974) (32)
Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor (2007) (32)
Gi affects the agonist-binding properties of beta-adrenoceptors in the presence of Gs. (1988) (31)
Transmembrane signalling to adenylate cyclase in mammalian cells and in Saccharomyces cerevisiae. (1988) (31)
Mechanism of negative cooperativity in glyceraldehyde-3-phosphate dehydrogenase deduced from ligand competition experiments. (1980) (31)
The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor. (2007) (31)
The activation of adenylate cyclase by 1‐epinephrine and guanylylimidodiphosphate and its reversal by 1‐epinephrine and GTP (1977) (31)
pp60(cSrc) is a caspase-3 substrate and Is essential for the transformed phenotype of A431 cells. (2000) (31)
The β-Adrenergic Receptor and its Mode of Coupling to Adenylate Cyclas (1981) (30)
The mode of coupling of adenylate cyclase to hormone receptors and its modulation by GTP. (1978) (29)
EGFR-Homing dsRNA Activates Cancer-Targeted Immune Response and Eliminates Disseminated EGFR-Overexpressing Tumors in Mice (2010) (29)
The ontogenesis of β-adrenergic receptors and of adenylate cyclase in the developing rat brain (1984) (29)
Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. (1999) (29)
Beta subunit copurifies with GppNHp-activated adenylyl cyclase. (1990) (29)
RNA molecules as anti-cancer agents. (2004) (29)
Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. (1994) (29)
Convergence of Logic of Cellular Regulation in Different Premalignant Cells by an Information Theoretic Approach (2011) (28)
The refolding of lactate dehydrogenase subunits and their assembly to the functional tetramer. (1976) (28)
Ligand competition curves as a diagnostic tool for delineating the nature of site-site interactions: theory. (1979) (28)
Tyrphostins inhibit the epidermal growth factor receptor‐mediated breakdown of phosphoinositides (1989) (28)
The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer (2014) (28)
An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. (2000) (28)
Adenylate cyclase activity of NIH 3T3 cells morphologically transformed by ras genes (1986) (27)
Optimization of Energy-Consuming Pathways towards Rapid Growth in HPV-Transformed Cells (2007) (27)
The interaction of catecholamines, Ca2+ and adenylate cyclase in the intact turkey erythrocyte. (1975) (27)
Anti-Cdc25 antibodies inhibit guanyl nucleotide-dependent adenylyl cyclase of Saccharomyces cerevisiae and cross-react with a 150-kilodalton mammalian protein (1992) (27)
Abortive complexes of -amylases with lanthanides. (1973) (27)
The tryphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. (1997) (26)
Affinity label for beta-adrenergic receptor in turkey erythrocytes. (1976) (26)
Reconstitution of a functional beta-adrenergic receptor using cholate and a novel method for its functional assay. (1983) (26)
The N-terminal half of Cdc25 is essential for processing glucose signaling in Saccharomyces cerevisiae. (1999) (26)
Copper-Induced Radiolytic Deactivation of α-Amylase and Catalase (1966) (26)
Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). (2011) (25)
Eighty thousand β-adrenoreceptors in a single cell (1977) (25)
16. CTP Synthetase and Related Enzymes (1974) (25)
Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by Staphylococcus aureus Cowan I. (1991) (25)
Effects of tyrphostins on the activated c-src protein in NIH/3T3 cells. (1994) (25)
Stochastic algorithm for kinase homology model construction. (2004) (24)
Shift from Apoptotic to Necrotic Cell Death during Human Papillomavirus-induced Transformation of Keratinocytes* (2009) (24)
Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions. (2010) (24)
The role of the nicotinamide and adenine subsites in the negative co-operativity of coenzyme binding to glyceraldehyde-3-phosphate dehydrogenase. (1977) (24)
An irreversible blocker for the β-adrenergic receptor (1976) (24)
The attenuation of epinephrine-dependent adenylate cyclase by adenosine and the characteristics of the adenosine stimulatory and inhibitory sites. (1979) (24)
The effect of copper on the radiosensitivity of bacteria. (1970) (24)
Tyrphostins inhibit follicle-stimulating hormone-mediated functions in cultured rat ovarian granulosa cells. (1993) (23)
A comparative study of NAD+ binding sites in dehydrogenases by circular polarization of fluorescence. (1975) (23)
Subunit neighbor interactions in enzyme kinetics: half-of-the-sites reactivity in a dimer. (1980) (23)
The regulatory control of β-receptor dependent adenylate cyclase (1976) (23)
Distinct roles of the receptor tyrosine kinases c-ErbB and c-Kit in regulating the balance between erythroid cell proliferation and differentiation. (1997) (22)
The reversal of the Gpp(NH)p-activated state of adenylate cyclase by GTP and hormone is by the "collision coupling" mechanism. (1981) (22)
Specific oxidation of peptides via their copper complexes. (1967) (22)
An analysis on the slope of Scatchard plots. (1976) (22)
Prostaglandin-stimulated GTP hydrolysis associated with activation of adenylate cyclase in human platelet membranes. (1982) (21)
The assembly pathway of lactic dehydrogenase isozymes from their unfolded subunits (1972) (21)
Suppression of Experimental Autoimmune Encephalomyelitis by Tyrphostin AG-556 (1998) (21)
High-performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in mouse plasma. (2001) (20)
Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors. (2010) (20)
Oxidase-like Activity of the Copper (II) Poly-L-histidine Complex (1965) (20)
The sequential nature of the negative cooperativity in rabbit muscle glyceraldehyde-3-phosphate dehydrogenase. (1980) (20)
Lateral mobility of β-receptors involved in adenylate cyclase activation (1980) (20)
Association of turkey erythrocyte beta‐adrenoceptors with a specific lipid component. (1986) (20)
Expression and purification of active PKB kinase from Escherichia coli. (2005) (20)
Theories and predictions of models describing sequential interactions between the receptor, the GTP regulatory unit, and the catalytic unit of hormone dependent adenylate cyclases. (1981) (20)
Active Src Elevates the Expression of (cid:2) -Catenin by Enhancement of Cap-Dependent Translation‡ (2005) (19)
Two distinct regions of Ras participate in functional interaction with GDP-GTP exchangers. (1995) (19)
Desensitization of normal rat kidney cells to adenosine. (1983) (19)
The GppNHp‐activated adenylyl cyclase complex from turkey erythrocyte membranes can be isolated with its βγ subunits (1992) (19)
Protein Kinase Inhibitors as a Therapeutic Modality (2003) (18)
The mechanism of partial agonism in the beta-receptor dependent adenylate cyclase of turkey erythrocytes. (1979) (18)
Metabolic Stability of Peptidomimetics: N‐Methyl and Aza Heptapeptide Analogs of a PKB/Akt Inhibitor (2011) (18)
Reconstitution of the turkey erythrocyte adenylate cyclase sensitivity to 1-epinephrine upon re-insertion of the Lubrol solubilized components into phospholipid vesicles. (1982) (18)
Co-operative response of oligomeric protein receptors coupled to non-co-operative ligand binding. (1975) (18)
Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-12951 (2002) (18)
Cloning of the STE5 gene of Saccharomyces cerevisiae as a suppressor of the mating defect of cdc25 temperature-sensitive mutants. (1993) (18)
Targeted cancer therapy: promise and reality. (2007) (18)
The signal transduction between β-receptors and adenylyl cyclase (1993) (17)
Signal Transduction Interception as a Novel Approach to Disease Management (1995) (17)
Targeting the Immune System to Fight Cancer Using Chemical Receptor Homing Vectors Carrying Polyinosine/Cytosine (PolyIC) (2012) (17)
The role of sulfhydryl groups in the action and structure of mammalian α-amylase (1974) (17)
A Candida albicans homolog of CDC25 is functional in Saccharomyces cerevisiae. (1993) (17)
Tyrphostin AG 494 blocks Cdk2 activation (1997) (16)
Differential activation of yeast adenylyl cyclase by Ras1 and Ras2 depends on the conserved N terminus. (1995) (16)
The quantitative aspects of drug-receptor interactions. (1975) (15)
ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. (2007) (15)
The allosteric activation of mammalian alpha-amylase by chloride. (1974) (15)
Cross-talk between PKC and cyclic AMP pathways (1987) (14)
Ligand-induced association-dissociation as a means for enzyme purification. (1970) (14)
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer (2019) (14)
Commentary: Gene Therapy for Glioblastoma: Future Perspective for Delivery Systems and Molecular Targets (2001) (13)
The Kinase Inhibitor PP 1 Blocks Tumorigenesis Induced by RET Oncogenes 1 (2002) (13)
Inhibitors of tyrosine kinases in the treatment of psoriasis. (2000) (13)
Signal Transduction Therapy for Cancer - Whither Now? (2006) (13)
A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells. (2005) (13)
Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks (2018) (12)
The interaction of concanavalin A with methyl alpha-D-glucopyranoside. (1968) (12)
GTP-GDP exchange proteins. (1990) (12)
Adenylyl cyclase activity of the fission yeast Schizosaccharomyces pombe is not regulated by guanyl nucleotides (1990) (12)
A possible molecular mechanism for beta-receptor desensitization: experiments and hypotheses. (1981) (12)
Tyrphostin‐induced differentiation of mouse erythroleukemia cells (1993) (12)
Characteristics of high-affinity [3H]adenosine binding to rat brain synaptosomes and turkey erythrocyte membranes. (1982) (12)
Probing of beta-adrenergic receptors by novel fluorescent beta-adrenergic blockers. (1977) (11)
Kinetics of phosphorylation of the SH2‐containing domain of phospholipase Cγ1 by the epidermal growth factor receptor (1994) (11)
Quinoxalines versus indolinones as inhibitors of restenosis. (2001) (11)
Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery. (2014) (11)
Negative cooperativity at the insulin receptor (1981) (11)
Evidence for ligand-induced conformational changes in rabbit-muscle glyceraldehyde-3-phosphate dehydrogenase. (1979) (11)
A color discriminating broad range cell staining technology for early detection of cell transformation (2009) (11)
Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors. (1997) (11)
N-Bromoacetyl-amino-cyanopindolol: a highly potent beta-adrenergic affinity label blocks irreversibly a non-protein component tightly associated with the receptor. (1985) (10)
The effect of early and late treatment with the tyrphostin AG-556 on the progression of experimental autoimmune myocarditis. (2004) (10)
Tumor specific activation of PKR as a non-toxic modality of cancer treatment. (2003) (10)
Alpha-cyanocinnamide derivatives: a new family of non-peptide, non-sulfhydryl inhibitors of Ras farnesylation. (1999) (10)
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). (2014) (10)
Modification of the radiolytic oxidation of ribonuclease induced by bound copper. (1967) (10)
Subunit S5a of the 26S proteasome is regulated by antiapoptotic signals (2007) (10)
The interaction of Mn2+ with turkey erythrocyte adenylate cyclase. (1982) (9)
Erbstatin and tyrphostins block protein-serine kinase activation and meiotic maturation of sea star oocytes. (1991) (9)
Fluorescent visualization of β‐adrenergic receptors on cell surfaces (1978) (9)
PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice (2017) (9)
Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases. (1998) (9)
Preparation and characterization of hormone-sensitive, resealed erythrocyte ghosts. (1976) (9)
GTP-receptor interrelationships in adenylate cyclase systems. Theoretical considerations. (1980) (9)
Slow GDP dissociation from the guanyl nucleotide site of turkey erythrocyte membranes is not the rate limiting step in the activation of adenylate cylase by β‐adrenergic receptors (1980) (9)
Tyrosine kinase blockers: new platelet activation inhibitors. (1990) (9)
Heterogeneity of Gene Expression in Murine Squamous Cell Carcinoma Development—The Same Tumor by Different Means (2013) (9)
Characterization of the beta 2-adrenoceptor-dependent adenylate cyclase of A431 epidermoid carcinoma cells. (1987) (9)
The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. (2003) (9)
Activation of dsRNA dependent protein kinase PKR in Karpas299 does not lead to cell death (2005) (8)
Rapid intracellular alkalinization of Saccharomyces cerevisiae MATa cells in response to alpha-factor requires the CDC25 gene product. (1989) (8)
EGF receptor family: twisting targets for improved cancer therapies (2014) (8)
Interaction between the Saccharomyces cerevisiae CDC25 gene product and mammalian ras. (1992) (7)
Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF (2016) (7)
Arylamides of hydroxylated isoquinolines as protein-tyrosine kinase inhibitors (1992) (7)
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. (2011) (7)
Royal academy of medicine in Ireland Section of biological sciences (1982) (7)
Amino acid starvation sensitizes cancer cells to proteasome inhibition (2010) (7)
Disruption of microtubules in living cells by tyrphostin AG-1714. (2000) (7)
Tyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat. (2003) (7)
The beta-adrenergic receptor and its mode of coupling to adenylate cyclase. (1981) (7)
Analytical determination of receptor-ligand dissociation constants of two populations of receptors from displacement curves. (1990) (7)
HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment (2016) (6)
Loss of Robustness and Addiction to IGF1 during Early Keratinocyte Transformation by Human Papilloma Virus 16 (2007) (6)
Mechanism of control of the turkey erythrocyte beta-adrenoceptor dependent adenylate cyclase by guanyl nucleotides: a minimum model. (1982) (6)
Dimers as Intermediates in the Assembly of Tetrameric Proteins: A Study on Lactate Dehydrogenase Isozymes (1974) (6)
Re-evaluation of the number of specific β-adrenergic receptors on muscle cells (reply) (1979) (5)
Correction: EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice (2007) (5)
PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses (2017) (5)
Lateral mobility of beta-receptors involved in adenylate cyclase activation. (1980) (5)
Activation of adenylate cyclase from purified platelet membranes by prostaglandin E1 and its inhibition by L-epinephrine: mechanistic effects. (1982) (5)
Bacterial adaptation, visual adaptation, receptor desensitization — a common link? (1986) (5)
Special Types of Cooperative Systems (1978) (4)
THE MECHANISM OF NEGATIVE COOPERATIVITY IN RABBIT MUSCLE GLYCERALDEHYDE‐3‐PHOSPHATE DEHYDROGENASE (1981) (4)
The Complex Regulation of HIC (Human I-mfa Domain Containing Protein) Expression (2009) (4)
The signal transduction between beta-receptors and adenylyl cyclase. (1993) (4)
Introduction: signal transduction therapy-10 years later. (2004) (4)
The hormonal regulation of adenylate cyclase. (1986) (4)
Guanine nucleotide regulation of adenylate cyclase in permeabilized cells of Saccharomyces cerevisiae. (1988) (4)
Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas (2002) (4)
The effect of tyrphostin AG-556 on intimal thickening in a mouse model of arterial injury. (2005) (3)
Effect of selective PDGF-receptor versus non-selective protein tyrosine kinase blockers on aortic smooth muscle cells (SMC's) and endothelial cells proliferation (1996) (3)
Inter-relations between beta-adrenergic receptors, adenylate cyclase and calcium. (1975) (3)
Signal transduction in hormone-dependent adenylate cyclase (2008) (3)
The GppNHp-activated adenylyl cyclase complex from turkey erythrocyte membranes can be isolated with its beta gamma subunits. (1992) (3)
Tyrphostin AG 555 Inhibits Bovine Papillomavirus Transcription by Changing the Ratio between E2 Transactivator/Repressor Function* (2003) (3)
Eighty thousand beta-adrenoreceptors in a single cell. (1977) (3)
Fluorescent visualization of beta-adrenergic receptors on cell surfaces. (1978) (3)
Erratum to ‘Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries’ [Biomaterials 26 (2005) 451–461] (2005) (3)
Catecholamine receptors. (1978) (2)
S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock (2018) (2)
Studying protein-peptide interactions using benzophenone units: a case study of protein kinase B/Akt and its inhibitor PTR6154. (2012) (2)
Basic Concepts of Allosteric Control (1978) (2)
Contribution of gross chromosomal changes to HPV16-induced transformation. (2011) (2)
Involvement of tyrosine kinase activity in platelet activation (1990) (2)
Tyrphostins inhibit FSH and cAMP mediated functions in rat ovarian granulosa cells: Possible involvement of tyrosine phosphorylation (1992) (2)
CHAPTER 3 – THE REGULATION OF ADENYLYL CYCLASE BY RECEPTOR-OPERATED G PROTEINS (1993) (2)
Formation of the bis(biuretato)-complex of tervalent copper and its redox potential (1968) (2)
The selectivity of small molecules towards protein tyrosine kinases. (2001) (2)
Nucleic acid-based therapeutics for glioblastoma. (2011) (2)
Invitro reconstitution ofCDC25regulated S.cerevisiae adenylyl cyclase anditskinetic properties (1990) (2)
The Energy of Subunit Interactions (1978) (2)
The ontogenesis of beta-adrenergic receptors and of adenylate cyclase in the developing rat brain. (1984) (2)
Resolution, reconstitution, and mode of action of the beta-adrenergic receptor-dependent adenylate cyclase. (1984) (1)
Molecular Models for Cooperativity and Allosteric Interactions (1978) (1)
Specific oxidation of copper binding sites in copper(II)--oligopeptide complexes. (1971) (1)
From Tyrphostins to Iressa and Gleevec: Signal Transduction Therapy from Concept to the Patient Bed (2003) (1)
Mechanism for the assembly of spherical viruses: a geometrical approach. (1972) (1)
Cooperativity in Multisubunit Proteins — The Basic Concepts (1978) (1)
G-Protein Subunit Dissociation Is not an Integral Part of G-Protein Action (2002) (1)
Activation and inhibition of adenylate cyclase by hormones. (1982) (1)
Tentative identification of beta-adrenoreceptor subunts. (1978) (1)
All about synapse function (1978) (1)
The β-Adrenergic Receptors and Their Mode of Interaction with Adenylate Cyclase (1984) (1)
Targeting the immune system to cancer (2011) (1)
Small Molecule Therapeutics The Tyrphostin NT 157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer (2014) (1)
Effect of non-selective protein tyrosine kinase blocker on porcine aortic, human arterial, and atheroma-derived SMC's proliferation (1996) (1)
INTERLEUKIN-12 Enhances the antitumor effect of the tyrosine kinase inhibitor AG-490 in a murine myeloma model (2000) (1)
CHAPTER 77 – Protein Kinase Inhibitors (2003) (1)
The interaction of chlorpromazine and butyrophenones with glutamate dehydrogenase. (1981) (0)
Use of inhibitors of the receptor of platelet-derived growth factors for preparing a medicament for the treatment of cancer (1995) (0)
Inhibitory GTP binding protein G/sub i/ regulates US -adrenoceptor affinity towards US -agonists (1987) (0)
Tyrphostins. Part 5. Potent Inhibitors of Platelet‐Derived Growth Factor Receptor Tyrosine Kinase: Structure‐Activity Relationships in Quinoxalines, Quinolines, and Indole Tyrphostins. (1996) (0)
Pharmaceutical compositions containing tyrphostins (1997) (0)
Use of inhibitors of the platelet-fragments of muscles growth factor receptor for the manufacture of a lægmiddel to Behan (1995) (0)
Amifostine pretreatment allows the use of higher doses' of the bcr-abl-specific tyrosine kinase innibitor agh12 (1997) (0)
T yr p ho s t in-I nd uced In hi bi t ion of p 2 1 Obcr-ab' Tyrosine Kinase Activity Induces K562 to Differentiate (2017) (0)
Derivatives 2- (2-phenylethenyl) -1,3-benzothiazol useful for treating cancer (2011) (0)
The regulatory control of beta-receptor dependent adenylate cyclase. (1976) (0)
Passing on the message: Molecular mechanisms of transmembrane signalling edited by P. Cohen and Miles D. Houslay, Elsevier Biomedical Press 1985. US$116.75 (xxiv + 487 pages) ISBN Series: 0-444 80225 8; Vol: 0 444 80689 X (1986) (0)
Regulation of Adenylate Cyclase in Mammalian Cells and Saccharomyces Cerevisiae (1989) (0)
Protein Tyrosine Kinase Inhibitors as Antiangiogenic Agents (2008) (0)
Probing of fl-adrenergic receptors by novel fluorescent fl-adrenergic blockers (0)
Compounds for the treatment of diseases associated with of vasculogenesis and / or angiogenesis in connected. (1995) (0)
Double-stranded RNA vector with EGFR as targets for SYSTEMIC CANCER TREATMENT (2009) (0)
Use of electrofocusing for the analysis and purification of turkey erythrocytes β1‐adrenoceptors (1988) (0)
Peripheral tolerance and lymphocyte anergy (PP-072) (2010) (0)
TheBinding Characteristics andNumberoff-Adrenergic Receptors ontheTurkeyErythrocyte (8-receptors/isoproterenol/propranolol/equilibrium dialysis/ultracentrifugation) (1974) (0)
An irreversible blocker for the beta-adrenergic receptor. (1976) (0)
IL09 Interception of cellular signaling as a novel modality for treatment of disease (1996) (0)
1170 EGFR-Ta:RNA: multimodal mechanism of action potentiates immune checkpoint inhibitor activity (2022) (0)
PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions containing these compounds (2000) (0)
Erratum: Phosphorylation of the S. cerevisiae Cdc25 in response to glucose results in its dissociation from Ras (1993) (0)
Abstract PD2-07: Insulin receptor substrate (IRS) targeting by the tyrophostin NT157 inhibits breast cancer cell growth (2016) (0)
Abstract B243: Targeting HER-2 positive breast cancer by inducing apoptosis and immune cell activation, overcoming trastuzumab resistance. (2013) (0)
Table of Contents (1990) (0)
Signal Transduction in the β-Adrenoceptor-Dependent Adenylate Cyclase (1988) (0)
Table of Contents (1992) (0)
74 Targeting the Immune System to Cancer (2012) (0)
Interception of tyrosine kinase signaling pathways as a therapeutic modality (1997) (0)
Abstract 2698: Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I) (2014) (0)
Tyrphostines ssi et compositions pharmaceutiques (1994) (0)
Styryl heteroaryl which inhibit EGF receptor tyrosine kinase (1991) (0)
Outward pressure within erythrocytes. (1981) (0)
Mammalian Glyceraldehyde-3-Phosphate Dehydrogenase and its Use to Elucidate Molecular Mechanisms of Cooperativity (2020) (0)
Vector dsRNA directed to EGFR for systemic treatment of cancer (2009) (0)
Gastrointestinal tumor Intermediate myelofibrosis Polycythemia vera Non-small-cell lung cancer Chronic myeloid leukemia Breast cancer Renal cell carcinoma Medullary thyroid cancer Vandetanib Lapatinib (2012) (0)
The Structure of Multisubunit Proteins (1978) (0)
The coupling of receptors to adenylate cyclases [proceedings]. (1980) (0)
Characterization of the β-Adrenergic Receptor and the Regulatory Control of Adenylate Cyclase (1976) (0)
The closure of Sugen (2003) (0)
S2-Signal transduction (2007) (0)
Compounds for treating diseases of cell proliferation (2004) (0)
Isolated Adenylate Cyclase and β-Adrenergic Receptor (1984) (0)
The potential of tyrphostins for the therapy of breast cancer. (2000) (0)
Where Do We Stand on Receptors Today (1984) (0)
Binding Ligands to Receptors: Additional Comments (1984) (0)
styryl-substituted heteroaryl compounds that inhibit tyrosine kinase EGF receptor. (1991) (0)
Selected titles (2006) (0)
1062 Signal transduction therapy (2003) (0)
Towards a PKB inhibitor (2001) (0)

This paper list is powered by the following services:

Other Resources About Alexander Levitzki

en.wikipedia.org

What Schools Are Affiliated With Alexander Levitzki?

Alexander Levitzki is affiliated with the following schools:

Alexander Levitzki's Academic­Influence.com Rankings

Why Is Alexander Levitzki Influential?

Alexander Levitzki's Published Works

Published Works

Other Resources About Alexander Levitzki

What Schools Are Affiliated With Alexander Levitzki?

Image Attributions

Alexander Levitzki's AcademicInfluence.com Rankings